95 results

Understanding the Role of the Kappa Opioid Receptor in Ketamine's Attenuation of Suicidal Thoughts (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 4 12 participants New York State Psychiatric Institute

Major Depressive Disorder (MDD)

Biomarker-Guided Antidepressant Selection (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 4 27 participants Weill Medical College of Cornell University

Depression - Major Depressive Disorder, Treatment-resistant Depression (TRD), rTMS, Ketamine

Esketamine Versus Crisis Response Planning Versus Enhanced Treatment as Usual for Suicide Prevention: A Pragmatic Randomized Trial in a Brazilian Municipality (SAVE) (opens ClinicalTrials.gov in a new tab)

Suspended Phase 4 468 participants University of Sao Paulo

Suicide Prevention, Ketamine, Crisis Response Plan

Esketamine With or Without Integration Therapy for Treatment-Resistant Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 4 20 participants University of Puerto Rico

Treatment-resistant Depression (TRD)

Ketamine for Postherpetic Neuralgia With Depression (opens ClinicalTrials.gov in a new tab)

Not yet recruiting Phase 4 50 participants Huazhong University of Science and Technology

Depression Disorders, Herpetic Neuralgia

A Study of Esketamine Nasal Spray in Korean Participants With Treatment-resistant Depression (opens ClinicalTrials.gov in a new tab)

Completed Phase 4 47 participants Janssen Korea, Ltd., Korea

Depressive Disorder, Treatment-Resistant

Precision Care for Major Depressive Disorder (opens ClinicalTrials.gov in a new tab)

Enrolling by invitation Phase 4 150 participants University of California, San Francisco

Major Depressive Disorder, Depression, Depressive Disorder, Major

The Effect of Outpatient Ketamine Infusion on Chronic Neuropathic Pain and PTSD (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 4 30 participants Margaux M. Salas, PhD

Neuropathic Pain, PTSD

Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 4 162 participants The George Institute

Treatment Resistant Depression

Ketamine-assisted Therapy for Advanced GI Cancer (opens ClinicalTrials.gov in a new tab)

Terminated Phase 4 1 participants Brian Anderson, MD

Pancreatic Ductal Adenocarcinoma, Pain, Acute, Gastrointestinal Cancers, Demoralization

Neural Circuit Effects of Ketamine in Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 4 120 participants Icahn School of Medicine at Mount Sinai

Major Depressive Disorder

Feasibility and Effectiveness of a Specific App to Delivery Mindfulness Sessions (opens ClinicalTrials.gov in a new tab)

Completed Phase 4 30 participants Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta

Migraine, Neuropathic Pain

Positioning of Esketamine Treatment in the Real-world Management of Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 4 162 participants Royal North Shore Hospital

Major Depressive Disorder

Impact of Ketamine On Depressive Symptoms In Patients Undergoing Lumbo-peritoneal Shunt Insertion (opens ClinicalTrials.gov in a new tab)

Completed Phase 4 110 participants Benha University

Depression, Anxiety

VA Aripiprazole vs Esketamine for Treatment Resistant Depression (opens ClinicalTrials.gov in a new tab)

Withdrawn Phase 4 0 participants VA Office of Research and Development

Depressive Disorder, Major

Randomized, Double-blind, Placebo-controlled Cannabis Extract x Placebo for Cocaine Addicts (opens ClinicalTrials.gov in a new tab)

Unknown status Phase 4 60 participants University of Sao Paulo General Hospital

Cocaine Dependence

Psychotherapy for Ketamine's Enhanced Durability in Chronic Neuropathic Pain: A Randomized Controlled Pilot Trial (opens ClinicalTrials.gov in a new tab)

Completed Phase 4 30 participants Unity Health Toronto

Neuropathic Pain

Comparative Effectiveness of ECT vs. KETAMINE Over the Lifespan (opens ClinicalTrials.gov in a new tab)

Enrolling by invitation Phase 4 1,500 participants Brigham and Women's Hospital

Acute Suicidal Depression (ASD)

Effect of Low-dose Esketamine on Maternal Depression at 3 Years After Childbirth (opens ClinicalTrials.gov in a new tab)

Active, not recruiting Phase 4 364 participants Peking University First Hospital

Prenatal Depression, Ketamine, Postpartum Depression

Comparing Mescaline Sodium Enteric-coated Tablets vs Morte-mescaline in the Treatment of Adult Lupus Nephritis (opens ClinicalTrials.gov in a new tab)

Unknown status Phase 4 205 participants Xiangya Hospital of Central South University

Lupus Nephritis

An EEG Study of Intravenous Ketamine for Major Depression Disorder (opens ClinicalTrials.gov in a new tab)

Unknown status Phase 4 35 participants Ehave Inc.

Major Depressive Disorder

Oral Aspirin + Ketamine as Adjunct to Oral Antidepressant Therapy for Depression (opens ClinicalTrials.gov in a new tab)

Completed Phase 4 15 participants Theresa Jacob, PhD, MPH

Treatment Resistant Depression, Major Depressive Disorder, Analgesia, Ketamine

Long-Term Maintenance With Ketamine and Esketamine for Reduction of Suicide in High-Risk Patients With Depression (opens ClinicalTrials.gov in a new tab)

Recruiting Phase 4 100 participants Massachusetts General Hospital

Major Depressive Disorder

Anhedonia, Development, and Emotions: Phenotyping and Therapeutics (opens ClinicalTrials.gov in a new tab)

Completed Phase 4 123 participants Erika Forbes

Depression, Anhedonia

Mindfulness and Biofeedback for Anxiety Disorders (opens ClinicalTrials.gov in a new tab)

Completed Phase 4 188 participants I.M. Sechenov First Moscow State Medical University

Anxiety Disorders